MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies_Pain
Latigo Biotherapeutics Inc.
Organization & Developments: Latigo Biotherapeutics
Parents
Latigo Biotherapeutics Inc.
Children
*Developing innovative non-opioid pain medicines with potential best-in-class profiles that directly target the source of pain.
*Drug discovery company developing novel, non-opioid therapies for chronic pain.
2024: Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
2025: Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
Jumps
Finance & Acquisition: Latigo Biotherapeutics
Key People: Latigo Biotherapeutics